



ASX / Media Release
8 November 2023

Invex Appoints David Wheeler as Non-Executive Director

Invex Therapeutics Ltd (Invex, ASX:IXC, or the Company) a biopharmaceutical company focused on the development and commercialisation of Presendin™ (sustained release Exenatide) for neurological conditions relating to raised intracranial pressure today announces the appointment of Mr David Wheeler as a Non-Executive Director of the Company, effective 8 November 2023.

David has more than 30 years of Senior Executive Management, Directorships, and Corporate Advisory experience. He is a foundation Director and Partner of Pathways Corporate a boutique Corporate Advisory firm that undertakes assignments on behalf of family offices, private clients, and ASX listed companies. David is a Fellow of the Australian Institute of Company Directors (FAICD). He is currently Non-Executive Chairman of Protean Energy Ltd, PVW Resources Ltd and Avira Resources Ltd and a Non-Executive Director of Ragnar Metals Ltd, Tyranna Resources Ltd, MOAB Ltd, Cycliq Group Ltd, Cradle Resources Ltd and OZZ Resources Ltd.

Mr David McAuliffe, Non-Executive Chairman of Invex Therapeutics said “On behalf of the Board, we welcome David as a Non-Executive Director of the Company. As Invex completes its close-out of the IIH EVOLE Phase III clinical trial and the \$14.0 million capital return before the end of the year, David’s expertise will be welcomed as Invex explores the continued development of our Exenatide program, while in parallel exploring strategic options to complement our activities.”

- ENDS -

This release dated 8 November 2023 has been authorised for lodgement to ASX by the Board of Directors of Invex Therapeutics.

For more information, please contact:

Company/Investors

Dr Thomas Duthy
Executive Director
tduthy@invextherapeutics.com
+61 402 493 727

Media

Margie Livingston
Ignite Communications
margie@ignitecommunications.com.au
+61 438 661 131

To subscribe to Invex email alerts, please visit www.invextherapeutics.com and follow us on Twitter [@InvexThera_ASX](https://twitter.com/InvexThera_ASX)

About Invex Therapeutics Ltd

Invex is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure. Invex has trademarked its repurposed Exenatide as Presendin™. www.invextherapeutics.com.